Chelsea Therapeutics, Inc. to Discuss NORTHERA(TM) (droxidopa) NDA for the Treatment of Symptomatic Neurogenic OH at FDA Advisory Committee Meeting on February 23

CHARLOTTE, N.C., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will meet with the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on Thursday, February 23, 2012 to review clinical data in support of the New Drug Application (NDA) for NORTHERA™ (droxidopa). Chelsea is seeking approval of NORTHERA for the treatment of symptomatic neurogenic orthostatic hypotension (known as Neurogenic OH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.